The groundbreaking rise of Viagra has long been a benchmark of pharmaceutical success, however its legacy within the broader industry now presents questions about potential returns . Copycat versions are diminishing market share, leading to worries that supporting companies closely tied to Viagra's former influence could be a problematic strategy,